PatSnap/clinical-trial huggingface dataset:
Clinical trial NCT02913417: Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
Official title: A Feasibility Study of Sequential Hepatic Internal Radiation and Systemic Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastatic to Liver.
Conditions: Uveal Melanoma
Hepatic Metastases
Summary: Reports to date show limited efficacy of immunotherapy for uveal melanoma. Recent experimental and clinical evidence suggests synergy between radiation therapy and immunotherapy. The investigators will explore this synergy with a feasibility study of 26 patients with uveal melanoma and hepatic metastases who will receive SirSpheres Yttrium-90 selective internal hepatic radiation followed by immunotherapy with the combination of ipilimumab and nivolumab.
Interventions:
description: Patient treatment will consist of three parts: first, selective internal radiation with SIR-Spheres Yttrium-90 microspheres with dosage per package insert , reduced to give 35cGymax to normal liver; second, concurrent ipilimumab 1mg/kg and nivolumab 1mg/kg every 3 weeks for 4 doses (immunotherapy part 1); then maintenance nivolumab at 480 every 2 weeks (immunotherapy part 2) until progression or 3 years
name: SIR-Spheres® Yttrium 90
type: Device
description: ipilimumab 1mg/kg every 3 weeks x 4
name: ipilimumab
other_name: Yervoy
type: Drug
description: nivolumab 3mg/kg every 3 weeks x 4 then 480mg q 4 weeks
name: nivolumab
other_name: Opdivo
type: Drug
Study arms:
design_group_description: SIR-Spheres Yttrium 90 will be given by injection into the hepatic artery in two treatments, one for each lobe. 3-5 weeks later patients receive concurrent ipilimumab 1mg/kg q 3 wk x 4 and nivolumab 3mg/kg q 3 weeks x 4, all followed by nivolumab 240mg/kg q 2 weeks or 480 mg q 4 weeks until progression or 3 years
design_group_title: hepatic radiation followed by immunotherapy
design_group_type: Experimental
Sponsor: California Pacific Medical Center Research Institute
Collaborators: The University of Chicago
Sidney Kimmel Medical College
California Pacific Medical Center
Drug name mappings:
name: 伊匹木单抗
lang: CN
name: Ipilimumab
lang: EN
name: イピリムマブ（遺伝子組換え）
lang: JP
name: 纳武利尤单抗
lang: CN
name: Nivolumab
lang: EN
name: ニボルマブ（遺伝子組換え）
lang: JP
Clinical trial NCT06495307: RHPRG4 FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)
Official title: A PHASE I PROSPECTIVE OPEN LABEL STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)
Conditions: Ocular Graft-versus-host Disease
Summary: rhPRG4-GVHD-001 is a prospective multi-center study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in subjects with moderate to severe dry eye secondary to chronic GVHD.
Interventions:
description: Sterile isotonic aqueous solution containing rhPRG4 (450 µg/mL) for topical administration, 10 mM sodium phosphate, 150 mM sodium chloride & 0.01% polysorbate 20 at pH 7.2. In all subjects, both eyes will be treated
name: rhPRG4
type: Drug
Study arms:
design_group_title: Treatment
design_group_type: Experimental
Sponsor: Lubris BioPharma
Collaborators: Lubris BioPharma
Drug name mappings:
name: Recombinant Human Proteoglycan 4(Lubris BioPharma)
lang: EN
Clinical trial NCT06598202: Exploring Nasal Drop Therapy With Small Extracellular Vesicles for ALS
Official title: An Exploratory Study on the Use of Intranasal Administration of Small Extracellular Vesicles for the Treatment of Amyotrophic Lateral Sclerosis
Conditions: Amyotrophic Lateral Sclerosis
Summary: This is a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. The goal of this clinical trial is to evaluate the safety and preliminary efficacy of nasal drop exosomes derived from human umbilical cord blood mesenchymal stem cells (hUC-MSC-sEV-001) in amyotrophic lateral sclerosis.
Interventions:
description: Exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop (administered once daily, twice a week, for a total of two weeks, based on the recommended dose during the dose-escalation phase).
name: exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop
other_name: hUC-MSC-sEV-001
type: Drug
description: Exosomes placebo
name: a placebo of exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop
other_name: hUC-MSC-sEV-001 placebo
type: Drug
Study arms:
design_group_description: Patients in this arm will receive exosomes derived from human umbilical cord blood mesenchymal stem cells as a nasal drop, administered once daily, twice a week, for a total of two weeks.
design_group_title: Exosomes group
design_group_type: Experimental
design_group_description: Patients in this arm will receive a placebo nasal drop mimicking exosomes derived from human umbilical cord blood mesenchymal stem cells, administered once daily, twice a week, for a total of two weeks.
design_group_title: Exosomes placebo group
design_group_type: Placebo Comparator
Sponsor: Xuanwu Hospital Capital Medical University
Collaborators: Shengqi Medical Technology (Guangzhou) Co., Ltd.
Drug name mappings:
name: HUC-MSC-sEV-001 Nasal Drops(Xuanwu Hospital )
lang: EN
Clinical trial NCT00863369: Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
Official title: A Phase I/II Study of VELCADE in Combination With Gemcitabine in Relapsed B-Cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma
Summary: RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with gemcitabine hydrochloride and rituximab may kill more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of bortezomib and gemcitabine hydrochloride when given together with rituximab and to see how well they work in treating patients with progressive or relapsed B-cell non-Hodgkin lymphoma.
Interventions:
description: Given IV
name: rituximab
other_name: IDEC-C2B8
IDEC-C2B8 monoclonal antibody
MOAB IDEC-C2B8
Mabthera
Rituxan
type: Biological
description: Given IV
name: bortezomib
other_name: LDP 341
MLN341
VELCADE
type: Drug
description: Given IV
name: gemcitabine hydrochloride
other_name: Gemzar
dFdC
difluorodeoxycytidine hydrochloride
gemcitabine
type: Drug
description: Ancillary studies
name: questionnaire administration
type: Other
Study arms:
design_group_description: Patients receive bortezomib IV, gemcitabine hydrochloride IV over 3-4 hours, and rituximab IV on days 1 and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
design_group_title: Treatment (bortezomib, gemcitabine hydrochloride, rituximab)
design_group_type: Experimental
Sponsor: City of Hope National Medical Center
Collaborators: National Cancer Institute
Drug name mappings:
name: 盐酸吉西他滨
lang: CN
name: Gemcitabine Hydrochloride
lang: EN
name: ゲムシタビン塩酸塩
lang: JP
name: 硼替佐米
lang: CN
name: Bortezomib
lang: EN
name: ボルテゾミブ
lang: JP
name: 利妥昔单抗
lang: CN
name: Rituximab
lang: EN
name: リツキシマブ（遺伝子組換え）
lang: JP
Clinical trial NCT01211457: Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Official title: A Phase I/II Combination Study of Sapacitabine in Acute Myeloid Leukemia or Myelodysplastic Syndromes
Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes
Summary: This is a combination study to evaluate sapacitabine administered in alternating cycles with decitabine in previously untreated Acute Myeloid Leukemia (AML) or concomitantly with venetoclax in previously treated AML or MDS
Interventions:
description: decitabine will be administered in alternating cycles with sapacitabine
name: sapacitabine and decitabine (Part 1 - completed)
type: Drug
description: sapacitabine will be administered concomitantly with venetoclax
name: sapacitabine and venetoclax (Part 2 - recruiting)
type: Drug
Study arms:
design_group_description: decitabine will be administered in alternating cycles with sapacitabine
design_group_title: Sapacitabine/decitabine (Part 1 - completed)
design_group_type: Experimental
design_group_description: sapacitabine will be administered concomitantly with venetoclax
design_group_title: sapacitabine/venetoclax (Part 2 - recruiting)
design_group_type: Experimental
Sponsor: Bio Green Med Solution, Inc.
Collaborators: The University of Texas MD Anderson Cancer Center
Drug name mappings:
name: 维奈克拉
lang: CN
name: Venetoclax
lang: EN
name: ベネトクラクス
lang: JP
name: 地西他滨
lang: CN
name: Decitabine
lang: EN
name: 沙帕他滨
lang: CN
name: Sapacitabine
lang: EN
Clinical trial NCT01848067: Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Official title: A Phase I/II Study of Alisertib in Combination With Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer After Progression on Abiraterone
Conditions: Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer
Summary: This phase I/II trial studies the side effects and best dose of alisertib when given together with abiraterone acetate and prednisone and to see how well it works in treating patients with hormone-resistant prostate cancer. Alisertib and abiraterone acetate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Androgens can cause the growth of prostate cancer cells. Drugs, such as abiraterone acetate, may also lessen the amount of androgens made by the body. Drugs used in chemotherapy, such as prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving alisertib, abiraterone acetate, and prednisone together may be an effective treatment for prostate cancer.
Interventions:
description: Given PO
name: Alisertib
other_name: MLN8237
type: Drug
description: Given PO
name: Abiraterone acetate
other_name: Abiraterone
Zytiga
type: Drug
description: Given PO
name: Prednisone
other_name: Cortan
Deltasone
Orasone
Prednisone Intensol
Rayos
Sterapred
type: Drug
Study arms:
design_group_description: Patients receive alisertib PO BID on days 1-7, abiraterone acetate PO daily, and prednisone PO BID. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
design_group_title: Treatment (alisertib, abiraterone acetate, prednisone)
design_group_type: Experimental
Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Collaborators: Millennium Pharmaceuticals, Inc.
Drug name mappings:
name: Alisertib
lang: EN
name: 泼尼松
lang: CN
name: Prednisone
lang: EN
name: 醋酸阿比特龙
lang: CN
name: Abiraterone acetate
lang: EN
name: アビラテロン酢酸エステル
lang: JP
Clinical trial NCT06084104: DZD9008 PK Study in Hepatic Impairment Subjects
Official title: A Phase 1, Single-Dose, Non-Randomized, Open Label Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of DZD9008
Conditions: Hepatic Impairment
Summary: This study will investigate the pharmacokinetics, safety, and tolerability of DZD9008 in subjects with hepatic impairment compared to subjects with normal hepatic function
Interventions:
description: A single oral dose of 200mg DZD9008
name: DZD9008
type: Drug
description: A single oral dose of 200mg DZD9008
name: DZD9008
type: Drug
Study arms:
design_group_description: Subjects with hepatic impairment
design_group_title: Hepatic impairment
design_group_type: Experimental
design_group_description: Subjects with normal hepatic function
design_group_title: Healthy Subject
design_group_type: Experimental
Sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Collaborators: PPD Development LP
Drug name mappings:
name: 舒沃替尼
lang: CN
name: Sunvozertinib
lang: EN
Clinical trial NCT04219163: Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen
Official title: Chimeric Antigen Receptor T-cells for The Treatment of Acute Myeloid Leukemia Expressing CLL-1 Antigen
Conditions: Acute Myeloid Leukemia
Summary: Patients eligible for this study have a type of blood cancer Acute Myeloid Leukemia (AML) which has come back or has not gone away after treatment.
The body has different ways of fighting disease and infection, and this research study combines two different ways of fighting cancer with antibodies and T cells with the hope that they will work together. T cells (also called T lymphocytes) are special infection-fighting blood cells that can kill other cells including tumor cells. Antibodies are types of proteins that protect the body from bacterial and other infectious diseases. Both antibodies and T cells have been used to treat patients with cancers; they have shown promise, but have not been strong enough to cure most patients when used alone.
T lymphocytes can kill tumor cells but there normally are not enough of them to kill all the tumor cells. Some researchers have taken T cells from a person's blood, grown more of them in the laboratory and then given them back to the person. The antibody used in this study targets CLL-1. This antibody sticks to AML cells because of a substance (protein) on the outside of these cells called CLL-1. For this study, the antibody to CLL-1 has been changed so that instead of floating free in the blood, it is now joined to the T cells. When T-cells contain an antibody that is joined to them, they are called chimeric antigen receptor T-cells or CAR-T cells.
In the laboratory, the investigators have also found that T cells work better if proteins that stimulate T cells are also added, such as one called CD28. Adding the CD28 makes the cells grow better and last longer in the body, thus giving the cells a better chance of killing the leukemia or lymphoma cells. In this study we are going to attach the CLL-1 chimeric receptor that has CD28 added to it to the patient's T cells. We will then test how long the cells last.
These CLL-1 chimeric antigen receptor T cells with CD28 are investigational products not approved by the Food and Drug Administration.
Interventions:
description: Dose escalation study with 3 dose levels:<br/>DL1: 1x10^7 cells/m2, DL2: 3x10^7 cells/m2, DL3: 1x10^8 cells/m2<br/>If excessive dose limiting toxicity attributed to the product occurs at dose level one, we will request permission from FDA to treat at dose level -1: 5×10^6 cells/m2
name: CLL-1.CAR T cells
type: Biological
Study arms:
design_group_description: Group A
design_group_title: CLL-1.CAR
design_group_type: Experimental
Sponsor: Baylor College of Medicine
Collaborators: Center For Cell & Gene Therapy
The Methodist Hospital Research Institute
Drug name mappings:
name: CLL-1.CAR T cell therapy(Baylor College of Medicine)
lang: EN
Clinical trial NCT01358721: Phase I Biomarker Study (BMS-936558)
Official title: An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Subjects With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Conditions: Renal Cell Carcinoma
Summary: The purpose of this study is to evaluate the pharmacodynamic and biologic properties of BMS-936558 in subjects with metastatic renal cell carcinoma.
Interventions:
description: Solution, Intravenous infusion, 0.3 mg/kg, Every 3 weeks, Indefinitely depending on response
name: BMS-936558 (Anti-PD-1)
type: Drug
description: Solution, Intravenous infusion, 2 mg/kg, Every 3 weeks, Indefinitely depending on response
name: BMS-936558 (Anti-PD-1)
type: Drug
description: Solution, Intravenous infusion, 10 mg/kg, Every 3 weeks, Indefinitely depending on response
name: BMS-936558 (Anti-PD-1)
type: Drug
Study arms:
design_group_title: Arm 1: BMS-936558
design_group_type: Experimental
design_group_title: Arm 2: BMS-936558
design_group_type: Experimental
design_group_title: Arm 3: BMS-936558
design_group_type: Experimental
design_group_description: (treatment naive)
design_group_title: Arm 4: BMS-936558
design_group_type: Experimental
Sponsor: Bristol Myers Squibb Co.
Collaborators: Ono Pharma USA, Inc.
Drug name mappings:
name: 纳武利尤单抗
lang: CN
name: Nivolumab
lang: EN
name: ニボルマブ（遺伝子組換え）
lang: JP
Clinical trial NCT02604498: Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function
Official title: Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function
Conditions: Liver Dysfunction
Summary: This is a single center, open-label, non-randomized, 1:1 parallel control and single dose administration study design. Healthy subjects will be matched to moderate hepatic function impaired (Child-Pugh B，7-9) subjects in age, gender and weight as parallel control, which matches healthy with normal hepatic function according to the of subjects with impaired hepatic function as, after enrollment of subjects with moderate impaired hepatic function (Child-Pugh B，7-9). Hepatic function impaired group and control group both receive orally single-dose of nemonoxacin malate capsule (0.5g). Collect the blood and urine samples before and after the administration to perform pharmacokinetic analysis and safety observation.
Interventions:
description: Single dose 500mg oral
name: Nemonoxacin
other_name: Nemonoxacin Malate Capsules
type: Drug
Study arms:
design_group_description: Subject with Moderate Impaired Hepatic Function. Nemonoxacin Malate Capsules 500mg single dose oral.
design_group_title: Liver function impaired
design_group_type: Experimental
design_group_description: Healthy volunteers. Nemonoxacin Malate Capsules 500mg single dose oral.
design_group_title: Healthy Subjects
design_group_type: Experimental
Sponsor: Zhejiang Medicine Co., Ltd.
Collaborators: Shanghai Huashan Hospital
Drug name mappings:
name: 苹果酸奈诺沙星
lang: CN
name: Nemonoxacin Malate
lang: EN
Clinical trial NCT00527761: Taxotere/Temodar/Cisplatin Study in Melanoma Patients
Official title: Phase I Study of TTC (Taxotere/Temodar/Cisplatin) in Metastatic Melanoma Patients
Conditions: Metastatic Melanoma
Summary: Primary Objective:
1. To determine the maximum tolerated dose of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma.
Secondary Objectives:
1. To determine the toxicity of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma
2. To determine the response rate of induction chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma.
Interventions:
description: 20 mg in 500 ml of normal saline by vein over 60 minutes daily for 4 days starting on day 1 of chemotherapy.
name: Cisplatin
other_name: CDDP
Platinol
Platinol-AQ
type: Drug
description: Starting dose 20 mg by vein over 1 hour, once a week, for three weeks (on Days 1, 8, and 15).
name: Docetaxel
other_name: Taxotere
type: Drug
description: 150 mg by mouth (PO) on Days 1 - 5.
name: Temodar
other_name: Temozolomide
type: Drug
Study arms:
design_group_title: Temozolomide, Docetaxel + Cisplatin
design_group_type: Experimental
Sponsor: The University of Texas MD Anderson Cancer Center
Collaborators: Aventis Pharmaceuticals, Inc.
Drug name mappings:
name: 替莫唑胺
lang: CN
name: Temozolomide
lang: EN
name: テモゾロミド
lang: JP
name: 顺铂
lang: CN
name: Cisplatin
lang: EN
name: シスプラチン
lang: JP
name: 多西他赛
lang: CN
name: Docetaxel
lang: EN
name: ドセタキセル
lang: JP
Clinical trial NCT02038972: Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss
Official title: Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss
Conditions: Sensorineural Hearing Loss
Summary: To determine if autologous human umbilical cord blood infusion in children with acquired hearing loss is safe, feasible, improves inner ear function, audition and language development.
Interventions:
description: The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.
name: Autologous Stem Cells
other_name: Cell based therapy
type: Genetic
Study arms:
design_group_description: A single dose of intravenously administered autologous hUCB will be done. The minimum acceptable dose will be 6x10 6th mononuclear cells/kilogram body weight. The hUCB reanimation, cell processing and product infusion will occur at Florida Hospital for Children and the Florida Hospital Center for Cellular Therapy.
design_group_title: Autologous Stem Cells
design_group_type: Experimental
Sponsor: AdventHealth Waterman
Collaborators: CBR Systems, Inc.
Drug name mappings:
name: Autologous Human Umbilical Cord Blood(AdventHealth)
lang: EN
Clinical trial NCT00540579: CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas
Official title: A Phase I/II Study of CC-4047 in Combination With Gemcitabine in Subjects With Untreated Advanced Carcinoma of the Pancreas
Conditions: Pancreatic Cancer
Summary: Because the activity of CC-4047 addresses numerous mechanisms of carcinoma growth inhibition - including, but not limited to anti-angiogenesis - CC-4047 has been selected for development as part of induction chemotherapy regimens for solid tumors. This study in pancreatic cancer is designed to determine the appropriate CC-4047 dose and regimen in combination with gemcitabine.
Interventions:
description: Phase 1: Subjects will be enrolled in dose-escalating cohorts to be treated with CC-4047 on days 1-21 Phase II: Subjects will be enrolled to receive oral CC-4047 at the MTD days 1 - 21
name: Pomalidomide
other_name: CC-4047
type: Drug
description: 1000 mg/m2 IV on days 1, 8, and 15 of 28 day cycle
name: Gemcitabine
other_name: Gemzar
type: Drug
Study arms:
design_group_description: All patients received gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of a 28 day cycle. Pomalidomide was administered orally on days 1-21 at doses escalated from 2 mg to 10 mg daily.
design_group_title: Intervention
design_group_type: Experimental
Sponsor: Scri Development Innovations LLC
Collaborators: Celgene Corp.
Drug name mappings:
name: 盐酸吉西他滨
lang: CN
name: Gemcitabine Hydrochloride
lang: EN
name: ゲムシタビン塩酸塩
lang: JP
name: 泊马度胺
lang: CN
name: Pomalidomide
lang: EN
name: ポマリドミド
lang: JP
Clinical trial NCT00639392: Phase 1 Study of Zoledronic Acid in Sickle Cell Disease
Official title: Phase 1 Study of Zoledronic Acid in Sickle Cell Disease
Conditions: Sickle Cell Disease
Summary: The long-term goal of this study is to learn if Zoledronic Acid can prevent or reduce pain in sickle cell disease. The goal of this study is to learn about the safety of Zoledronic Acid in persons with sickle cell disease who experience chronic pain requiring medical treatment or use of narcotics.
Interventions:
description: Patients will receive a single dose of placebo administered by vein over about 15 minutes. Placebo is mostly water without Zoledronic Acid.
name: Placebo
type: Drug
description: Patients will receive a single dose of Zolendronic Acid. Zoledronic Acid is administered by vein over about 15 minutes.
name: Zoledronic Acid
type: Drug
Study arms:
design_group_description: Patients will receive a single dose of Zoledronic Acid or placebo. The chances that a subject will receive placebo are 1 out of 3.
design_group_title: 2
design_group_type: Placebo Comparator
design_group_description: Patients will receive a single dose of Zoledronic Acid or placebo. The chances that a subject will receive Zolendronic Acid are 2 out of 3.
design_group_title: 1
design_group_type: Experimental
Sponsor: Virginia Commonwealth University
Collaborators: Novartis AG
Drug name mappings:
name: 唑来膦酸
lang: CN
name: Zoledronic Acid
lang: EN
name: ゾレドロン酸水和物
lang: JP